<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003023</url>
  </required_header>
  <id_info>
    <org_study_id>97-024</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>MSKCC-97024</secondary_id>
    <secondary_id>NCI-G97-1268</secondary_id>
    <nct_id>NCT00003023</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer</brief_title>
  <official_title>Phase I Trial of A1G4 Anti-Idiotypic Monoclonal Antibody With Bacille-Calmette-Guerin (BCG) Adjuvant in High Risk Patients With GD2 Positive Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver&#xD;
      tumor-killing substances to them without harming normal cells. Combining monoclonal antibody&#xD;
      A1G4 with BCG may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody A1G4 plus BCG in&#xD;
      treating patients with cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess the toxicity and feasibility of immunizing patients with anti-idiotypic rat&#xD;
           monoclonal antibody A1G4 combined with Bacillus Calmette Guerin (BCG) adjuvant.&#xD;
&#xD;
        -  Determine whether immunization with A1G4 combined with BCG results in an immune response&#xD;
           directed against GD2 ganglioside in patients.&#xD;
&#xD;
      OUTLINE: All patients are treated with A1G4 diluted in sterile physiologic saline mixed with&#xD;
      Bacillus Calmette Guerin (BCG) organisms. The vaccine is injected intradermally in multiple&#xD;
      sites. Booster immunizations are administered during weeks 2, 4, 8, 12, 20, 28, 36, 44, 52.&#xD;
      Immunizations are not administered in limbs where draining lymph nodes have been surgically&#xD;
      removed or previously irradiated. Isoniazid is administered for 5 days after each BCG&#xD;
      injection. If severe skin reactions are present at the injection site, the BCG dose is&#xD;
      decreased. If skin reactions persist, the BCG dose is stopped but A1G4 injections continue.&#xD;
&#xD;
      At least 6 patients are accrued at each dose level of A1G4. Dose escalation is not carried&#xD;
      out until patients have been followed for at least 8 weeks after the first immunization&#xD;
      without encountering grade 3 or worse non-skin toxicity.&#xD;
&#xD;
      If 0-1 patient experiences dose limiting toxicity (DLT) at a given dose level, then patients&#xD;
      are accrued to the next higher dose level. If 2 or more patients experience DLT, the MTD is&#xD;
      defined as the previous dose level.&#xD;
&#xD;
      Patients are followed for at least 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients are expected to complete this study. If patients&#xD;
      are removed early from the study prior to evaluation for serological response, additional&#xD;
      patients will be accrued until 6 patients are evaluable for serological response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1997</start_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Neuroblastoma</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>monoclonal antibody A1G4 anti-idiotype vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed GD2 positive tumors which include:&#xD;
&#xD;
               -  High risk neuroblastoma (stage IV, or N-myc amplified, or localized neuroblastoma&#xD;
                  multiply recurrent)&#xD;
&#xD;
               -  Recurrent or metastatic osteosarcoma&#xD;
&#xD;
               -  Recurrent or metastatic GD2 positive sarcomas&#xD;
&#xD;
          -  If free of disease, patient must be fully recovered from toxic effects or&#xD;
             complications of prior treatments (chemotherapy or surgery)&#xD;
&#xD;
               -  No greater than 6 months since last chemotherapy or surgery before first&#xD;
                  injection of A1G4&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 500/mm^3&#xD;
&#xD;
          -  Absolute leukocyte count greater than 500/mm^3&#xD;
&#xD;
          -  Peripheral T-cell phytohemagglutinin activation (PHA) at least 50% of normal&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No significant heart disease (NYHA class III or IV)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other serious intercurrent illnesses&#xD;
&#xD;
          -  No active infections requiring antibiotics&#xD;
&#xD;
          -  No active bleeding&#xD;
&#xD;
          -  No primary immunodeficiency&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Adequate contraception required of all fertile patients&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent antibiotics&#xD;
&#xD;
          -  No prior mouse antibodies and detectable human antimouse antibody (HAMA) titer&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 weeks since nitrosoureas&#xD;
&#xD;
          -  At least 4 weeks since other systemic chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent nonsteroidal anti-inflammatory agents&#xD;
&#xD;
          -  No concurrent corticosteroid&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since radiotherapy&#xD;
&#xD;
          -  No prior radiation therapy to the spleen&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No splenectomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nai-Kong V. Cheung, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 17, 2013</last_update_submitted>
  <last_update_submitted_qc>January 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <keyword>metastatic osteosarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

